CND 261
Alternative Names: CND-261Latest Information Update: 26 Jun 2025
At a glance
- Originator Genor Biopharma
- Developer Candid Therapeutics
- Class Antineoplastics; Antirheumatics; Bispecific antibodies; Immunotherapies; Recombinant fusion proteins; Skin disorder therapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Cancer
- Clinical Phase Unknown Rheumatoid arthritis; Systemic scleroderma